137 related articles for article (PubMed ID: 3181445)
1. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
Hershman MJ; Habib NA; Kelly SB; Beynon J; Williamson RC; Davies PW; Wood CB
Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with CA-50 in the serum of carcinoma patients.
Habib NA; Hershman MJ; Kelly SB; Taylor G; Williamson RC; Wood CB
Eur J Surg Oncol; 1989 Aug; 15(4):361-6. PubMed ID: 2759254
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
8. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of a tumor-associated antigen CA 15-3 in the sera of patients with breast cancer].
Ogawa T; Izuo M; Morita H; Ishida T; Iino Y; Hoshino K; Yokoe T; Suzuki H; Murata S; Matsuzaki S
Gan No Rinsho; 1986 Jan; 32(1):27-32. PubMed ID: 3456454
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
11. Experience with CA 15.3 as a tumor marker in breast cancer.
Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
[TBL] [Abstract][Full Text] [Related]
12. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study.
Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D
Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
Durdević S; Segedi D; Vejnović T; Radeka G
Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
[TBL] [Abstract][Full Text] [Related]
16. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
17. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic-like substance in breast fluid discharge in benign and malignant breast disease and in milk of lactating women.
Kahana L; Bartal AH; Yechieli H; Guttman I; Sheinfeld M
Isr J Med Sci; 1981 Nov; 17(11):1035-40. PubMed ID: 7319791
[TBL] [Abstract][Full Text] [Related]
19. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
Blind PJ; Dahlgren ST
Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
